Annual Results Momentum Building on our Commercial Plans
Filed with ASX · · 3 pages · English
Melbourne, Australia, 31 August 2023: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to report annual results for the year ended June 30, 2023. GTG has had an exciting period of commercial growth over the last 12 months in our Business to Business (B2B) channel led
Genetic Technologies Limited on 6ix
In the deck
Story so far
Earlier from Genetic Technologies
- 2023 Annual Report and Appendix 4E
- Updated Investor Presentation - August 2023
- Appendix 4C and Quarterly Activities Report - June 2023
- Publication Validates geneType for Melanoma Risk Assessment
- Appendix 4C & Quarterly Activities Report - March 2023
Later from Genetic Technologies
- geneType Granted Approval for 3 New Diseases in Australia
- MRFF Grant Names GTG as Sole Industry Partner
- GTG & Gold Coast Hospital Announce Precision Medicine Pilot
- Appendix 4C and Quarterly Activities Report - September 2023
- Consolidation/Split - GTG
Follow Genetic Technologies into a list and get an email when it puts out news.
Follow Genetic Technologies